



Xellia Pharmaceuticals welcomes Michael Kocher as its new Chief Executive Officer

Copenhagen, Denmark, 2 October 2023 – Xellia Pharmaceuticals ('Xellia'), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, today welcomes Michael Kocher as its new Chief Executive Officer.

With more than a decade of experience in commercial leadership roles at Novartis and Sandoz, Michael Kocher has significant expertise in the complexities of the global pharmaceutical landscape. His tenure at Sandoz, where he served as Global Head of Commercial Operations and subsequently as Global Head of B2B, underscored his pivotal role in transforming the company into a leading global partner within the industry. A native of Germany and a trained chemist, Michael Kocher's expertise and vision align with Xellia Pharmaceuticals' commitment to delivering anti-infective treatments and critical care therapies.

Steen Riisgaard, Chairman of Xellia, said, *"Michael's extensive experience and his role in securing the supply of essential anti-infectious medicines aligns perfectly with Xellia's underlying objective to save lives through innovating critical care and anti-infective therapies. On behalf of the Board and senior leadership, I am delighted to welcome Michael to the Xellia team."*

Michael Kocher, CEO of Xellia, added: *"I have long admired Xellia which has a 120-year heritage in the anti-infective space and holds an essential role in the stewardship of antibiotics worldwide. It has transformed itself from an API supplier into an integrated specialty pharma company with an international footprint across nine countries and an enviable 500+ customer list across more than 80 countries."*

"My first job is to immerse myself into the workings of the business, and most importantly, meet as many of the highly skilled and specialist team at Xellia as possible over the coming months. My aim as CEO is to ensure that the Company keeps doing its essential work in the antibiotic sector. I am really looking forward to getting started."

Xellia Pharmaceuticals' underlying mission is to provide a secure and consistent supply of critical care therapies to patients around the world. Operating across Europe, Asia, the Middle East and North America, the Company continues to invest in its global vertically integrated supply chain. This includes in-house production of Active Pharmaceutical Ingredients (APIs) and drug products, alongside collaboration with Xellia's R&D centers of excellence. The overarching goal is to enhance patient care by delivering convenience and ease of use for healthcare professionals.

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Steen Riisgaard, Chairman of the Board of Directors / Michael Kocher, CEO

Tel: +45 32 64 55 00

Email: info.dk@xellia.com

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Rozi Morris/ Batoul Ali

Tel: +44 (0) 20 7457 2020

Email: xellia@instinctif.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals is a specialty pharmaceutical company and a global leader in providing anti-infective treatments and other critical care therapies for serious and often life-threatening conditions. Xellia has an extensive history in developing, manufacturing, and commercializing anti-infective products, including Active Pharmaceutical Ingredients (APIs) as well as Finished Dosage Forms (FDFs), where the majority are injectable drug products.

As an organization, Xellia is committed to providing security and consistency of supply of critical care therapies. Through a global vertically integrated supply chain, the Company continuously works to improve supply security through multiple sources of in-house production of its APIs and drug products, and in conjunction through working alongside Xellia's R&D centers of excellence. Through innovation and with the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals. Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia Pharmaceuticals is wholly owned by Novo Holdings A/S and employs a dedicated team of more than 1,800 people.

Further information about Xellia can be found at: www.xellia.com

Connect with us on [LinkedIn](#)